FDA Convenes Workshop on Pediatric Antihypertensive Development, Targeting Evidence Gaps for Under-Six Population

Regulatory affairs leads preparing pediatric antihypertensive submissions should treat the FDA's July 15–16, 2026 public workshop as an early signal of where the agency intends to sharpen its evidence expectations, particularly for children younger than six years of age, where approved therapies remain scarce.

The workshop, co-hosted with the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), will convene clinicians, industry representatives, regulators, and patient caregivers at FDA's White Oak Campus in Silver Spring, Maryland, with a parallel webcast option. The two-day agenda is structured around four core questions: how disease pathophysiology and drug response differ across pediatric age bands; the extent to which adult efficacy data can be extrapolated to pediatric populations; development priorities for both first-line and resistant hypertension; and feasible evidence-generation strategies for the youngest cohorts.

The extrapolation question carries the most immediate operational weight. Products currently in development for uncontrolled or resistant hypertension in adults may hold pediatric utility, but sponsors will need to demonstrate where adult pharmacokinetic and pharmacodynamic assumptions hold and where age-specific studies are required. The workshop's framing suggests the agency is actively working through those boundaries before submission expectations are formalized.

For development teams, the under-six population represents the sharpest regulatory challenge. Dose-finding, formulation design, and endpoint selection all require pediatric-specific justification that cannot be fully bridged from adult data alone. Workshop outputs, including any draft frameworks on extrapolation thresholds or evidence sufficiency, are likely to inform future guidance and, by extension, the content reviewers will expect in pediatric study plans and labeling negotiations.

Registration is open for both in-person attendance at Building 31, Room 1503, 10903 New Hampshire Avenue, Silver Spring, MD 20993, and virtual participation via webcast. Day one runs 9:00 a.m. to 4:00 p.m. ET on July 15; day two runs 9:00 a.m. to 12:00 p.m. ET on July 16.

Sponsors with active or planned pediatric antihypertensive programs should track workshop proceedings closely, as stakeholder input gathered here is a documented step in the agency's evidence-generation roadmap for this indication.

Source: FDA Drugs News and Events (What's New: Drugs RSS Feed) via FDA.gov, published June 15, 2026; event scheduled July 15–16, 2026.